Drug Profile
Quizartinib - Daiichi Sankyo Company
Alternative Names: AC-010220; AC-220; ASP-2689; VANFLYTALatest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator Ambit Biosciences Corporation
- Developer Cancer Research UK; Cardiff University; Daiichi Sankyo Company; University Hospital Heidelberg; University of Texas M. D. Anderson Cancer Center
- Class 3-ring heterocyclic compounds; Antineoplastics; Benzothiazoles; Imidazoles; Isoxazoles; Morpholines; Phenylurea compounds; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia
- Phase II/III Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Discontinued Solid tumours
Most Recent Events
- 11 Dec 2023 Efficacy data from the phase-III QuANTUM-First trial in Acute Myeloid Leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition Session (ASH-Hem-2023)
- 09 Dec 2023 Efficacy data from a phase III QuANTUM-First trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Updated adverse events data from the phase III QuANTUM-First trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)